Cutaneous Squamous-Cell Carcinoma after Treatment with Ruxolitinib or Belumosudil
New England Journal of Medicine · 13.07.2023 · 389 (2) · 188-190
DOI: 10.1056/nejmc2304157 ↗Kurz gefasst
Leserbrief in der Zeitschrift New England Journal of Medicine, erschienen am 13.07.2023. Verfasst von Gun Ho Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital, Boston, MA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Squamous Cell, Skin Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Massachusetts General Hospital, Boston, MA.
- Brigham and Women's Hospital, Boston, MA.
- Dana-Farber Cancer Institute, Boston, MA.
- Brigham and Women's Hospital, Boston, MA cschmults@bwh.harvard.edu.
ORCID-Profile: Gun Ho Lee
Zitieren
APA
Lee, G. H., Guzman, A. K., Divito, S. J., Soiffer, R. J., Silk, A. W., & Schmults, C. D. (2023). Cutaneous Squamous-Cell Carcinoma after Treatment with Ruxolitinib or Belumosudil. New England Journal of Medicine, 389(2), 188-190. https://doi.org/10.1056/nejmc2304157
Vancouver
Lee GH, Guzman AK, Divito SJ, Soiffer RJ, Silk AW, Schmults CD. Cutaneous Squamous-Cell Carcinoma after Treatment with Ruxolitinib or Belumosudil. New England Journal of Medicine. 2023;389(2):188-190. doi:10.1056/nejmc2304157
BibTeX
@article{Lee2023,
author = {Lee, Gun Ho and Guzman, Anthony K and Divito, Sherrie J and Soiffer, Robert J and Silk, Ann W and Schmults, Chrysalyne D},
title = {Cutaneous Squamous-Cell Carcinoma after Treatment with Ruxolitinib or Belumosudil},
journal = {New England Journal of Medicine},
year = {2023},
volume = {389},
number = {2},
pages = {188--190},
doi = {10.1056/nejmc2304157}
}
EUVIMED